Bacterial Vaccines Market to grow with a CAGR of 7.20%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Bacterial Vaccines Market.
According
to TechSci Research report, “Global Bacterial Vaccines Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Bacterial Vaccines
Market has valued at USD 7.10 billion in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 7.20% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
Technological advances in bacterial vaccines
have played a crucial role in improving vaccine efficacy, safety, and
accessibility. These advances encompass various aspects of vaccine development,
from antigen identification and formulation to manufacturing and delivery
methods. The advent of genomics and bioinformatics has revolutionized the
identification of bacterial antigens. Scientists can now analyze bacterial
genomes to identify potential vaccine targets, including proteins,
polysaccharides, and other antigenic components. Reverse vaccinology is a
technique that involves using genomics to predict potential vaccine candidates.
This approach has been successful in identifying antigens for bacterial
vaccines, particularly for diseases caused by bacteria with complex genomes. Recombinant
DNA technology allows researchers to produce specific bacterial antigens in the
laboratory. These recombinant antigens can be used in subunit vaccines,
improving vaccine purity and safety. Conjugate vaccines involve attaching
bacterial polysaccharides to carrier proteins. This technology has been highly
effective in developing vaccines against bacterial pathogens like Haemophilus
influenzae type b (Hib) and Streptococcus pneumoniae. Advanced protein
expression systems, such as bacterial vectors and yeast-based platforms, are
used to produce large quantities of bacterial antigens for vaccine development.
These systems enhance the scalability and efficiency of vaccine production. Novel
adjuvants have been developed to enhance the immune response to bacterial
vaccines. Adjuvants like MF59 and AS01 are used in some vaccines to improve
their efficacy.
Bacterial
vaccines contain weakened or inactivated forms of bacteria, which serve as
crucial tools in preventive medicine to stimulate the immune system and combat
infections like tuberculosis, cholera, anthrax, influenza, tetanus, meningitis,
and typhoid. Governments and non-governmental organizations conduct various
initiatives aimed at raising awareness about the advantages of preventive
measures, including vaccination, to protect against infectious diseases.
In
September 2023, the first independent CDMO site for vaccines has been opened in
Suzhou, China, by WuXi Vaccines, a renowned contract development and
manufacturing organization (CDMO) with a focus on vaccine discovery,
development, and manufacture. With end-to-end services for a variety of
vaccines, the opening will increase the capacity for producing drug substances
and drug products. This will speed up the project timelines for global clients,
from process and drug product development to clinical-scale drug substance (DS)
and small- to medium-scale sterile drug product (DP) manufacturing. Its DS
production area has two cell culture lines, one purification line, and a
reserved capacity for 2,000L of output, allowing DS production sizes from 50L
to 1,000L. An automatic vial washing, sterilizing, filling, and capping line
that can support the clinical manufacturing of both liquid and lyophilized
products is available at the DP facility.
Antigen selection and development are
significant challenges in the Global Bacterial Vaccines Market. The choice of
antigens, which are the specific components of bacteria that are used to
stimulate an immune response, is a critical factor in the success of bacterial
vaccine development. Bacteria are incredibly diverse, and there are thousands
of different bacterial species with multiple strains and serotypes. Selecting
the right antigens that are common to a wide range of bacterial strains is a
complex task, as some antigens may only be effective against specific strains. Even
within a single bacterial species, there can be significant genetic
variability. This means that antigens effective against one strain may not work
against another. Vaccine developers must consider this variability when
selecting antigens. In some cases, antigens chosen for a vaccine may
cross-react with similar antigens in beneficial bacteria that inhabit the human
body. This can lead to unintended consequences, including disrupting the body's
microbiome. Antigens used in vaccines must be stable, meaning they should
remain effective and maintain their structural integrity during production,
storage, and administration. Ensuring the stability of antigens can be
challenging.
Browse
over XX market data Figures and spread through 110 Pages and an in-depth TOC
on "Bacterial Vaccines Market.”
Global Bacterial Vaccines Market is segmented based
on Vaccine Type, Patient Age Group, Distribution Channel, Route of
Administration, and by region.
Based on Vaccine
Type, Global Bacterial Vaccines Market is segmented into Pertussis (Whooping
Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal
Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines,
Shigellosis Vaccines, Others. Tetanus
vaccines are vaccines designed to protect individuals from tetanus, a
potentially deadly bacterial infection caused by the bacterium Clostridium
tetani. Tetanus is characterized by severe muscle stiffness, spasms, and
paralysis and is often referred to as lockjaw due to the muscle stiffness it
causes. Tetanus vaccines have been highly effective in preventing this serious
disease. Tetanus vaccines
contain inactivated tetanus toxin or toxoid. This toxoid is a chemically
modified form of the tetanus toxin, which is no longer capable of causing
disease but can still stimulate an immune response. Tetanus vaccines stimulate the immune system
to produce antibodies against the tetanus toxin. These antibodies provide
protection by neutralizing the toxin if the individual is exposed to
Clostridium tetani.
Based on Region, North America dominated the Global Bacterial Vaccines Market. North America
has stringent but well-defined regulatory processes for vaccine approval and
safety. The U.S. Food and Drug Administration (FDA) and Health Canada are known
for their rigorous evaluation of vaccines, which helps ensure product safety
and efficacy. There is a significant market demand for vaccines in North
America, driven by public health initiatives, vaccination programs, and a
generally high awareness of the importance of vaccination. The region is home
to several major vaccine manufacturers, some of which have been pivotal in
developing and distributing bacterial vaccines. North America is often seen as
a leader in global healthcare, which extends to vaccine development and
distribution. Its influence on global health policies and initiatives can
further enhance its role in the bacterial vaccines market. The region has
experienced outbreaks of bacterial diseases in the past, which has prompted
increased investment in research and development for bacterial vaccines.
Asia-pacific region to witness fastest growth in the
Global Bacterial Vaccines Market.
The Asia-Pacific region is home to a massive and diverse population, including
densely populated countries like China and India. The sheer size of the
population creates a substantial market for vaccines, including bacterial
vaccines, to address public health needs. Many countries in the Asia-Pacific
region have been increasing their investments in healthcare infrastructure and
systems. Improved healthcare access and infrastructure facilitate the
distribution and administration of vaccines, boosting market growth. The region
has seen a significant increase in the size of the middle class with greater
disposable income. As people's economic status improves, they are more likely
to seek and afford vaccines, contributing to market growth. Several countries
in the Asia-Pacific region have robust government-led immunization programs.
These programs aim to protect the population from vaccine-preventable diseases,
including bacterial infections. Government support drives vaccine demand and
uptake.
Some
of the major companies operating in the Global
Bacterial Vaccines Market include:
- Pfizer
Inc.
- GSK
plc
- Novartis
AG
- Mylan
N.V.
- Sanofi
- Boehringer
Ingelheim International GmbH.
- Merck
& Co., Inc.
- F.
Hoffmann-La Roche Ltd.
- Bristol-Myers
Squibb Company
- Bharat
Biotech
- Serum
Institute of India Pvt. Ltd
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Bacterial Vaccines. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Bacterial
Vaccines Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Bacterial Vaccines Market – Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Vaccine Type (Pertussis
(Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal
Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines,
Cholera Vaccines, Shigellosis Vaccines, Others), By Patient Age Group (Pediatric
Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric
Vaccines), By Distribution Channel (Government Agencies and Programs, Hospitals
and Clinics, Retail Pharmacies, Online Pharmacies, Others) , By Route of Administration
(Injectable Vaccines, Oral Vaccines, Nasal Vaccines), by region, and Competition evaluated
the future growth potential of Global Bacterial Vaccines Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Bacterial Vaccines Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com